MESOMICS - Rare Cancers Genomics

We are currently performing a full molecular characterization of malignant pleural mesothelioma types and subtypes through a multi-omic integrative analysis (WGS, RNA-seq, and 850k methylation arrays) of 126 primary tumors. The molecular data will be correlated with morphological, epidemiological, and clinical features.

We are also assessing the intra-tumor molecular heterogeneity of malignant pleural mesothelioma through a multi-omic integrative analysis (WGS, RNA-seq, and 850k methylation arrays) of different tumoral regions in a series of 13 mesothelioma patients.

PUBLICATIONS

 

Comprehensive molecular and pathological evaluation of transitional mesothelioma assisted by deep learning approach: a multi-institutional study of the International Mesothelioma Panel from MESOPATH Référence Center. Galateau Salle F, Le Stang N, Tirode F, Courtiol P, Nicholson AG, Tsao MS, Tazelaar HD, Churg A, Dacic S, Roggli V, Pissaloux D, Maussion C, Moarii M, Beasley MB, Begueret H, Chapel DB, Copin MC, Gibbs AR, Klebe S, Lantuejoul S, Nabeshima K, Vignaud JM, Attanoos R, Brcic L, Capron F, Chirieac LR, Damiola F, Sequeiros R, Cazes A, Damotte D, Foulet A, Giusiano-Courcambeck S, Hiroshima K, Hofman V, Husain AN, Kerr K, Marchevsky A, Paindavoine S, Picquenot JM, Rouquette I, Sagan C, Sauter J, Thivolet F, Brevet M, Rouvier P, Travis WD, Planchard G, Weynand B, Clozel T, Wainrib G, Fernandez-Cuesta L, Pairon JC, Rusch V, Girard N. 
J Thorac Oncol. 2020 PMID: 32165206

Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions. Alcala N, Mangiante L, Le-Stang N, Gustafon CE, Boyault S, Damiola F, Alcala K, Brevet M, Thivolet-Bejui F, Blanc-Fournier C, Le Rochais JP, Planchard G, Rousseau N, Damotte D, Pairon JC, Copin MC, Scherpereel A, Wasielewski E, Wicquart L, Lacomme S, Vignaud JM, Ancelin G, Girard C, Sagan C, Bonnetaud C, Hofman V, Hofman P, Mouroux J, Thomas de Montpreville V, Clermont-Taranchon E, Mazieres J, Rouquette I, Begueret H, Blay JY, Lantuejoul S, Bueno R, Caux C, Girard N, McKay JD, Foll M, Galateau-Salle F, Fernandez-Cuesta L. EBioMedicine 2019 PMID: 31648983. EBioMedicine editorial. IARC Press release

EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach. Nicholson AG, Sauter JL, Nowak AK, Kindler HL, Gill RR, Remy-Jardin M, Armato SG, Fernandez-Cuesta L, Bueno R, Alcala N, Foll M, Pass H, Attanoos R, Baas P, Beasley MB, Brcic L, Butnor KJ, Chirieac LR, Churg A, Courtiol P, Dacic S, De Perrot M, Frauenfelder T, Gibbs A, Hirsch FR, Hiroshima K, Husain A, Klebe S, Lantuejoul S, Moreira A, Opitz I, Perol M, Roden A, Roggli V, Scherpereel A, Tirode F, Tazelaar H, Travis WD, Tsao MS, van Schil P, Vignaud JM, Weynand B, Cree I, Rusch VW, Girard N, Galateau-Salle F. J Thorac Oncol. 2019 PMID: 31546041

Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes. Churg A, Nabeshima K, Ali G, Bruno R, Fernandez-Cuesta L, Galateau-Salle F. Lung Cancer 2018 PMID: 30268487

BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas. Leblay N, Leprêtre F, Le Stang N, Gautier-Stein A, Villeneuve L, Isaac S, Maillet D, Galateau-Sallé F, Villenet C, Sebda S, Goracci A, Byrnes G, McKay JD, Figeac M, Glehen O, Gilly FN, Foll M, Fernandez-Cuesta L, Brevet M. J Thorac Oncol. 2017 PMID: 28034829

OTHER SCIENTIFIC COMMUNICATIONS

 

Lise Mangiante gave an oral presentation entitled « Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interaction with clinical implications » in the 4th International Cancer Symposium of the Cancer Research Center of Lyons – October 2-4, 2019 in Lyons (France)

Lynnette Fernandez-Cuesta presented the molecular section of the « EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma » in the World Conference on Lung Cancer – September 7–10, 2019 in Barcelona (Spain)

Matthieu Foll gave an oral presentation entitled « Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular
interactions » in the World Conference on Lung Cancer – September 7–10, 2019 in Barcelona (Spain)

Lynnette Fernandez-Cuesta gave an oral presentation entitled « New insights into the molecular characteristics and intra-tumor heterogeneity of malignant pleural mesothelioma from the MESOMICS project » in the World Conference on Lung Cancer – September 7–10, 2019 in Barcelona (Spain)

Lise Mangiante presented a poster entitled « Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interaction with clinical implications » in the CLARA 2019 Cancer Research Forum – April 4-5, 2019 in Lyon (France)

Nicolas Alcala gave an oral presentation entitled « Clinical implications of a molecular malignant pleural mesothelioma classification: insights from the French MESOMICS project » in the IASLC-EURACAN Multidisciplinary Workshop on Mesothelioma Classification – July 6-7, 2018 in Lyon (France)

Lynnette Fernandez-Cuesta gave an oral presentation entitled « The French MESOMICS project for the multi-omics characterization of malignant pleural mesothelioma » in the 14th International Conference of the International Mesothelioma Interest Group – May 2-5, 2018 in Ottawa (Canada)

Nicolas Alcala presented a poster entitled « Projet français de caractérisation multi-omique du mésothéliome pleural malin » in the 1ères Journées Francophones du Mésothéliome – November 15-16, 2017 in Créteil (France)

FUNDING

 

Unveiling the intra-tumour heterogeneity of malignant mesothelioma. Ligue Contre le Cancer (LNCC, France). Coordinators. Completed.

Molecular characterisation of malignant pleural mesothelioma. Institut National Du Cancer (INCa, France). PRT-K16-039. Coordinators. Active.